Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67.094
Filtrar
1.
Blood Adv ; 8(17): 4727-4728, 2024 Sep 10.
Artigo em Inglês | MEDLINE | ID: mdl-39254966
2.
HLA ; 104(3): e15649, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39247998

RESUMO

HLA donor specific antibodies (DSA) are implicated in antibody-mediated rejection (AMR), graft dysfunction and failure in kidney transplant (KT) recipients. Non-HLA antibodies including angiotensin II type 1 receptor (AT1R) may also play a role in AMR, impact graft function and survival. Data is limited in paediatric KT cohorts. We aimed to assess the prevalence and effect of pre-transplant AT1R antibodies on rejection, graft function and survival in paediatric KT recipients. This was a retrospective cohort study conducted across two paediatric centres including KT recipients with a pre-transplant AT1R antibody level. Outcomes included rejection, de novo DSA formation, graft function, failure, proteinuria and hypertension. Of 71 individuals, 72% recorded a positive pre-transplant AT1R Ab level (≥17 U/mL). Over a median follow-up of 4.7 years, AT1R Ab positivity demonstrated a trend towards increased risk of rejection however was not statistically significant (HR 3.45, 95% CI 0.97-12.35, p-value 0.06). Sensitivity analysis with AT1R Ab levels of ≥25 U/mL (HR 2.05 95% CI 0.78-5.39, p-value 0.14) and ≥40 U/mL (HR 1.32, CI 95% 0.55-3.17, p-value 0.53) validated this. De novo DSA formation occurred more frequently with AT1R Ab positivity (41% vs. 20%, p-value 0.9). AT1R Ab was not associated with hypertension, proteinuria, graft failure or dysfunction. In conclusion, this cohort study demonstrated a high prevalence of pre-transplant AT1R Ab positivity (72%). AT1R Ab positivity demonstrated a trend towards increased risk of rejection and de novo DSA formation however did not meet statistical significance. There was no association between AT1R Ab and hypertension, proteinuria, graft failure or dysfunction.


Assuntos
Rejeição de Enxerto , Sobrevivência de Enxerto , Transplante de Rim , Receptor Tipo 1 de Angiotensina , Humanos , Receptor Tipo 1 de Angiotensina/imunologia , Rejeição de Enxerto/imunologia , Masculino , Estudos Retrospectivos , Feminino , Criança , Adolescente , Isoanticorpos/sangue , Isoanticorpos/imunologia , Pré-Escolar , Antígenos HLA/imunologia , Proteinúria/imunologia , Proteinúria/sangue , Hipertensão/imunologia , Hipertensão/fisiopatologia , Hipertensão/sangue
3.
Adv Kidney Dis Health ; 31(5): 408-415, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39232611

RESUMO

Over the last 7 decades, kidney transplantation has evolved from an experiment between identical twins to becoming the gold standard treatment for end-stage kidney disease. To date, mycophenolate and calcineurin inhibitors, with or without prednisone, continue to constitute the backbone of modern maintenance immunosuppression. Despite major strides in improving acute rejection, long-term outcomes remain suboptimal with current regimens. Alternatives to calcineurin inhibitors such as belatacept and mammalian targets of rapamycin inhibitors exist; however, their wider-scale adoption remains relatively delayed due to concerns about increased rejection rates. In addition to continuing the investigation of steroid and calcineurin inhibitor sparing protocols, it is time to identify measurable surrogates for meaningful long-term graft survival. iBOX, a dynamic risk-prediction tool that predicts long-term death-censored graft failure could be a potential surrogate end point for future immunosuppression clinical trials. In this review, we summarize the landmark studies supporting current immunosuppression protocols and briefly discuss challenges and future directions.


Assuntos
Rejeição de Enxerto , Imunossupressores , Transplante de Rim , Humanos , Imunossupressores/uso terapêutico , Rejeição de Enxerto/prevenção & controle , Rejeição de Enxerto/imunologia , Terapia de Imunossupressão/métodos , Sobrevivência de Enxerto/efeitos dos fármacos , Sobrevivência de Enxerto/imunologia , Falência Renal Crônica/cirurgia , Falência Renal Crônica/imunologia , Ácido Micofenólico/uso terapêutico , Inibidores de Calcineurina/uso terapêutico
4.
Adv Kidney Dis Health ; 31(5): 427-435, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39232613

RESUMO

Currently in the United States, there are more than 250,000 patients with a functioning kidney allograft and over 100,000 waitlisted patients awaiting kidney transplant, with a burgeoning number added to the kidney transplant wait list every year. Although early post-transplant care is delivered at the transplant center, the increasing number of kidney transplant recipients requires general nephrologists to actively participate in the long-term care of these patients. Serum creatinine and proteinuria are imperfect traditional biomarkers of allograft dysfunction and lag behind subclinical allograft injury. This manuscript reviews the various clinically available biomarkers in the field of kidney transplantation for a general nephrologist with a focus on the utility of donor-derived cell-free DNA, as a marker of early allograft injury. Blood gene expression profiling, initially studied in the context of early identification of subclinical rejection, awaits validation in larger multicentric trials. Urinary cellular messenger ribonucleic acid and chemokine CXCL10 hold promising potential for early diagnosis of both subclinical and acute rejection. Torque tenovirus, a ubiquitous DNA virus is emerging as a biomarker of immunosuppression exposure as peripheral blood torque tenovirus copy numbers might mirror the intensity of host immunosuppression. Although high-quality evidence is still being generated, evidence and recommendations are provided to aid the general nephrologist in implementation of novel biomarkers in their clinical practice.


Assuntos
Biomarcadores , Rejeição de Enxerto , Transplante de Rim , Humanos , Transplante de Rim/efeitos adversos , Biomarcadores/sangue , Biomarcadores/urina , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/sangue , Rejeição de Enxerto/imunologia , Ácidos Nucleicos Livres/sangue , Ácidos Nucleicos Livres/urina
5.
Adv Kidney Dis Health ; 31(5): 416-426, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39232612

RESUMO

It is important for providers caring for kidney transplant recipients to be familiar with the common causes of allograft dysfunction. Early detection of allograft dysfunction leads to timely management, with the goal of preventing or delaying progression to allograft failure. Although transplant rejection is always a concern, the differential diagnoses for allograft dysfunction are broad and include perioperative complications, infections, recurrent disease, and calcineurin nephrotoxicity. In this review, we will go over early and late causes of allograft dysfunction and discuss the basic workup and principles of management for each condition.


Assuntos
Rejeição de Enxerto , Transplante de Rim , Humanos , Transplante de Rim/efeitos adversos , Rejeição de Enxerto/prevenção & controle , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/imunologia , Aloenxertos , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/prevenção & controle
6.
Adv Kidney Dis Health ; 31(5): 476-482, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39232618

RESUMO

Survival rates for allografts have improved over the last 2 decades, yet failing allografts remains a challenge in the field of transplant. The risks of mortality and morbidity associated with failed allografts are compounded by infectious complications and metabolic abnormalities, emphasizing the need for a standardized approach to management. Management of failing allografts lacks consensus, highlighting the need for unified protocols to guide treatment protocols and minimize risks with postdialysis initiation. The decision to wean off immunosuppression depends on various factors, including living donor availability and infectious risks, necessitating improved coordination of care and a standard guideline. Treatment of failed pancreas focuses on glycemic control, with insulin as the mainstay, while considering surgical interventions such as graft pancreatectomy in advanced symptomatic cases. Navigating the complexities of failed allograft management demands a multidisciplinary approach and standardized stepwise protocol. Addressing the gaps in management plans for failing allografts and employing a systematic approach to transplant decisions will enhance patient outcomes and facilitate informed decision-making.


Assuntos
Transplante de Rim , Transplante de Pâncreas , Humanos , Transplante de Pâncreas/métodos , Transplante de Pâncreas/efeitos adversos , Transplante de Rim/efeitos adversos , Rejeição de Enxerto/prevenção & controle , Sobrevivência de Enxerto , Imunossupressores/uso terapêutico , Imunossupressores/efeitos adversos , Falha de Tratamento
7.
Clin Transplant ; 38(9): e15419, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39235071

RESUMO

PURPOSE: The aim of the study was to determine outcomes after heart transplantation for cytomegalovirus (CMV) mismatched patients (D+/R-) who underwent a surveillance and preemptive therapy protocol, compared to nonmismatch patients. METHODS: A review of patient records from January 2010 to December 2020 with follow-up to October 2023 was done. The protocol consisted weekly surveillance with CMV PCR starting 4 weeks after transplant continuing up until the patient seroconverts or up to 3 months posttransplant if the patient does not seroconvert. Valganciclovir was given for 2 weeks to those who seroconverted. RESULTS: Two hundred and twenty-one patients were included, and 23% were mismatched patients. Overall survival was not different between CMV groups (p = NS). Causes of death and morbidities were also not significantly different (p = NS). Sixty-six percent of mismatch patients seroconverted, and there was also a significantly older donor age in the seroconverted patients compared to nonseroconverted patients (41 ± 11 vs. 29 ± 12 years, p < 0.005), indicating a higher risk donor profile. A multivariate Cox regression including donor age showed that there was no increase in mortality in the seroconverted mismatches compared to nonmismatch patients (p = NS). CONCLUSIONS: There is no significant increased mortality or morbidity using a CMV surveillance and preemptive therapy protocol. The effect of donor age on seroconversion of mismatches requires further validation.


Assuntos
Antivirais , Infecções por Citomegalovirus , Citomegalovirus , Sobrevivência de Enxerto , Transplante de Coração , Humanos , Transplante de Coração/efeitos adversos , Transplante de Coração/mortalidade , Infecções por Citomegalovirus/prevenção & controle , Infecções por Citomegalovirus/virologia , Infecções por Citomegalovirus/epidemiologia , Feminino , Masculino , Citomegalovirus/isolamento & purificação , Seguimentos , Adulto , Prognóstico , Estudos Retrospectivos , Antivirais/uso terapêutico , Fatores de Risco , Rejeição de Enxerto/prevenção & controle , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/mortalidade , Taxa de Sobrevida , Pessoa de Meia-Idade , Complicações Pós-Operatórias/prevenção & controle , Doadores de Tecidos/provisão & distribuição
8.
Theranostics ; 14(12): 4844-4860, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39239518

RESUMO

Rationale: Understanding the immune mechanisms associated with liver transplantation (LT), particularly the involvement of tissue-resident memory T cells (TRMs), represents a significant challenge. Methods: This study employs a multi-omics approach to analyse liver transplant samples from both human (n = 17) and mouse (n = 16), utilizing single-cell RNA sequencing, bulk RNA sequencing, and immunological techniques. Results: Our findings reveal a comprehensive T cell-centric landscape in LT across human and mouse species, involving 235,116 cells. Notably, we found a substantial increase in CD8+ TRMs within rejected grafts compared to stable ones. The elevated presence of CD8+ TRMs is characterised by a distinct expression profile, featuring upregulation of tissue-residency markers (CD69, CXCR6, CD49A and CD103+/-,), immune checkpoints (PD1, CTLA4, and TIGIT), cytotoxic markers (GZMB and IFNG) and proliferative markers (PCNA and TOP2A) during rejection. Furthermore, there is a high expression of transcription factors such as EOMES and RUNX3. Functional assays and analyses of cellular communication underscore the active role of CD8+ TRMs in interacting with other tissue-resident cells, particularly Kupffer cells, especially during rejection episodes. Conclusions: These insights into the distinctive activation and interaction patterns of CD8+ TRMs suggest their potential utility as biomarkers for graft rejection, paving the way for novel therapeutic strategies aimed at enhancing graft tolerance and improving overall transplant outcomes.


Assuntos
Linfócitos T CD8-Positivos , Rejeição de Enxerto , Transplante de Fígado , Células T de Memória , Análise de Célula Única , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Humanos , Rejeição de Enxerto/imunologia , Animais , Camundongos , Células T de Memória/imunologia , Células T de Memória/metabolismo , Análise de Célula Única/métodos , Análise de Sequência de RNA/métodos , Subunidade alfa 3 de Fator de Ligação ao Core/genética , Subunidade alfa 3 de Fator de Ligação ao Core/metabolismo , Memória Imunológica , Masculino , Camundongos Endogâmicos C57BL , Antígenos CD/metabolismo , Antígenos CD/genética , Feminino , Pessoa de Meia-Idade , Proteínas com Domínio T
9.
Exp Clin Transplant ; 22(7): 540-550, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-39223812

RESUMO

OBJECTIVES: Chronic rejection remains the leading cause of progressive decline in graft function. Accumulating evidence indicates that macrophages participate in chronic rejection dependent on CD40-CD40L. The FOS family members are critical in inflammatory and immune responses. However, the mechanisms underlying the role of FOS family members in chronic rejection remain unclear. In this study, we aimed to elucidate the role and underlying mechanisms of FOS-positive macrophages regulated by CD40 that mediate chronic allograft rejection. MATERIALS AND METHODS: We downloaded publicly accessible chronic rejection kidney transplant single-cell sequencing datasets from the gene expression omnibus database. Differentially expressed genes between the CD40hi and CD40low macrophage chronic rejection groups were analyzed. We established a chronic rejection mouse model by using CTLA-4-Ig. We treated bone marrow-derived macrophages with an anti-CD40 antibody. We assessed expression of the FOS family by flow cytometry, real-time quantitative polymerase chain reaction, Western blotting, and immunofluorescence. We identified altered signaling pathways by using RNA sequencing analysis. We detected DNA specifically bound to transcription factors by using ChIP-sequencing, with detection of the degree of graft fibrosis and survival. RESULTS: FOS was highly expressed on CD40hi macrophages in patients with chronic transplantrejection. Mechanistically, we showed that CD40 activated NF-κB2 translocation into the nucleus to upregulate c-Fos and FosB expression, thus promoting chronic rejection of cardiac transplant.We showed thatNF-κB2 regulated c-Fos and FosB expression by binding to the c-fos and fosb promoter regions. Inhibition of c-Fos/activator protein-1 decreased graft fibrosis and prolonged graft survival. CONCLUSIONS: CD40 may activate transcription factor NF-κB2 translocation into the nucleus of macrophages to upregulate c-Fos and FosB expression, thus promoting chronic rejection of cardiac transplant. Inhibition of c-Fos/activator protein-1 decreased grafts fibrosis and prolonged graft survival.


Assuntos
Antígenos CD40 , Modelos Animais de Doenças , Rejeição de Enxerto , Transplante de Coração , Macrófagos , Proteínas Proto-Oncogênicas c-fos , Transdução de Sinais , Animais , Humanos , Masculino , Camundongos , Antígenos CD40/metabolismo , Antígenos CD40/genética , Células Cultivadas , Doença Crônica , Bases de Dados Genéticas , Fibrose , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/metabolismo , Rejeição de Enxerto/genética , Sobrevivência de Enxerto , Transplante de Coração/efeitos adversos , Macrófagos/imunologia , Macrófagos/metabolismo , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , NF-kappa B/metabolismo , Proteínas Proto-Oncogênicas c-fos/metabolismo , Proteínas Proto-Oncogênicas c-fos/genética , Fator de Transcrição AP-1/metabolismo
10.
J Med Virol ; 96(9): e29905, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39228322

RESUMO

Torque Teno Virus (TTV) is a non-pathogenic anellovirus, highly prevalent in healthy populations. Variations in its viral load have been associated with states of diminished immunity, as occurs after organ transplantation. It is hypothesized that TTV-load might be used as a diagnostic tool to guide prescription and dosing of immunosuppressive drugs. Not much is known about the effects of combined immunosuppressive drugs on TTV replication in renal transplantation. Belatacept was introduced to counter side-effects of calcineurin inhibitors (CNI). It was never widely adopted, mainly because its association with increased risk of rejection. To investigate the differential effects of a regimen based on calcineurin inhibitors versus belatacept on TTV-loads, we measured TTV-levels in 105 patients from two randomized controlled trials in kidney transplant recipients (KTRs). We observed that time after transplantation was inversely related to TTV-levels of patients that remained on a CNI-containing regime, whereas this decline over time was diminished after conversion to belatacept. In addition, a correlation with tacrolimus-trough levels and age were found. Our study is the first report on the impact of conversion from CNI to belatacept on TTV-levels in KTR. In conclusion, the time-related decline in TTV-levels is mitigated after conversion from CNI to belatacept.


Assuntos
Abatacepte , Inibidores de Calcineurina , Imunossupressores , Transplante de Rim , Torque teno virus , Carga Viral , Humanos , Transplante de Rim/efeitos adversos , Abatacepte/uso terapêutico , Inibidores de Calcineurina/uso terapêutico , Inibidores de Calcineurina/administração & dosagem , Imunossupressores/uso terapêutico , Imunossupressores/efeitos adversos , Masculino , Pessoa de Meia-Idade , Feminino , Torque teno virus/efeitos dos fármacos , Carga Viral/efeitos dos fármacos , Adulto , Infecções por Vírus de DNA/tratamento farmacológico , Infecções por Vírus de DNA/virologia , Idoso , Transplantados , Rejeição de Enxerto/prevenção & controle
11.
Exp Clin Transplant ; 22(7): 522-530, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-39223810

RESUMO

OBJECTIVES: Growing evidence has highlighted the substantial effects of COVID-19 on kidneys, ranging from mild proteinuria to severe acute kidney injury. However, comprehensive assessments of histopathological features in renal allograft biopsies are lacking. MATERIALS AND METHODS: Seventeen kidney transplant recipients with COVID-19 between March 2020 and November 2022 were evaluated. Clinical characteristics, pathological findings, and outcomes were studied. RESULTS: Six kidney transplant recipients (35.3%) developed acute kidney injury, leading to the requirement for hemodialysis. COVID-19 severity, as indicated by pneumonia (P = .028) and hospitalization (P = .002), was significantly associated with development of acute kidney injury. Most patients with COVID-19 (82.4%) showed considerably increased proteinuria levels (82.4%), along with presence of new-onset microscopic hematuria (35.3%) and nephrotic syndrome (58.8%). Tubular viral inclusionlike changes were detected in 47.1% of cases and were associated with a higher risk of graft loss (75%). Thrombotic microangiopathy and endothelial cell swelling in glomeruli were prevalent, highlighting extensive endothelial cell injury. Most recipients (88.2%) experienced rejection after COVID-19, with graft loss occurring in 46.7% of these cases. Biopsies revealed collapsing (n = 5), noncollapsing (n = 3), and recurrent (n = 2) focal segmental glomerulosclerosis, as well as acute tubulointerstitial nephritis (n = 3), crescentic glomerulonephritis with immunoglobulin A nephropathy (n = 1), and membranoproliferative glomerulonephritis (n = 1), in 129.7 ± 33 days. Eight patients experienced graft loss (8.2 ± 2 mo posttransplant). Hospitalization (P = .044) and viralinclusion-like nuclear changes in tubules (P = .044) significantly influenced graft survival. Collapsing (60%) and noncollapsing (66.7%) focal segmental glomerulosclerosis increased the risk of graft loss. CONCLUSIONS: COVID-19 has had a multifaceted and enduring effect on renal allografts, urging the need for meticulous monitoring and tailored management strategies to mitigate the risk of severe kidney-related complications and graft loss in this vulnerable population.


Assuntos
Injúria Renal Aguda , COVID-19 , Transplante de Rim , Humanos , COVID-19/epidemiologia , Transplante de Rim/efeitos adversos , Masculino , Feminino , Pessoa de Meia-Idade , Adulto , Fatores de Risco , Injúria Renal Aguda/epidemiologia , Injúria Renal Aguda/etiologia , Biópsia , Rejeição de Enxerto/imunologia , Aloenxertos , Resultado do Tratamento , Rim/patologia , Rim/virologia , Estudos Retrospectivos , Sobrevivência de Enxerto , Idoso , Medição de Risco
12.
Exp Clin Transplant ; 22(7): 531-539, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-39223811

RESUMO

OBJECTIVES: Primary sclerosing cholangitis is an autoimmune illness affecting the intrahepatic and/or extrahepatic bile ducts that has a varying clinical history and no clear therapy. Recurrence of primary sclerosing cholangitis after transplantation can cause recurring liver failure, decreased survival, and the necessity for retransplant. Here, we explored the incidence of recurrence while also identifying the risk factors of primary sclerosing cholangitis. MATERIALS AND METHODS: In this retrospective cohort study, we collected demographic and clinical data from patients with a history of primary sclerosing cholangitis after liver transplant between 2011 and 2021. With SPSS software, we compared results in 2 groups of patients (with and without recurrent sclerosing biliary cholangitis) in terms of demographic and clinical variables. RESULTS: The study included 408 patients. Lower donor age and the occurrence of acute cellularrejection were shown to be key risk factors for recurrence of primary sclerosing cholangitis. Acute cellularrejection showed the best likelihood of predicting primary sclerosing cholangitis recurrence. As the number of acute cellular rejection episodes increased, so did the chance of primary sclerosing cholangitis. Death rate of patients with recurrence of primary sclerosing cholangitis was 40.8% (n = 20 patients) compared with 18.9% (n = 68 patients) in those without recurrence (significant at P < .001). CONCLUSIONS: The recurrence of primary sclerosing cholangitis had a detrimental effect on survival after liver transplant. Modifiable risk variables have the potentialto affecttherapies on care and prevention of primary sclerosing cholangitis recurrence. Donor age and acute cellular rejection were risk factors for decreased survival and higher primary sclerosing cholangitis recurrence. The use of mycophenolate (Cellcept) increased recurrence, but tacrolimus reduced mortality.


Assuntos
Colangite Esclerosante , Imunossupressores , Transplante de Fígado , Recidiva , Humanos , Colangite Esclerosante/cirurgia , Colangite Esclerosante/mortalidade , Colangite Esclerosante/diagnóstico , Transplante de Fígado/efeitos adversos , Transplante de Fígado/mortalidade , Fatores de Risco , Estudos Retrospectivos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Resultado do Tratamento , Imunossupressores/efeitos adversos , Fatores de Tempo , Medição de Risco , Irã (Geográfico)/epidemiologia , Adulto Jovem , Incidência , Fatores Etários , Adolescente , Rejeição de Enxerto/mortalidade , Rejeição de Enxerto/prevenção & controle , Rejeição de Enxerto/diagnóstico , Rejeição de Enxerto/imunologia
13.
Transpl Int ; 37: 13452, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39263600

RESUMO

Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.


Assuntos
Sobrevivência de Enxerto , Transplante de Rim , Doadores Vivos , Pontuação de Propensão , Sistema de Registros , Humanos , Transplante de Rim/estatística & dados numéricos , Masculino , Feminino , Idoso , Estudos Retrospectivos , Europa (Continente) , Doadores de Tecidos , Fatores Etários , Rejeição de Enxerto , Resultado do Tratamento , Idoso de 80 Anos ou mais
14.
Transpl Int ; 37: 12874, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39267616

RESUMO

Non-adherence to immunosuppressive medication among transplant patients is associated with poor clinical outcomes and higher economic costs. Barriers to immunosuppressives are a proximal determinant of non-adherence. So far, international variability of barriers to adherence in transplantation has not been studied. As part of the cross-sectional multi-country and multi-center BRIGHT study, barriers to adherence were measured in 1,382 adult heart transplant recipients of 11 countries using the 28-item self-report questionnaire "Identifying Medication Adherence Barriers" (IMAB). Barriers were ranked by their frequency of occurrence for the total sample and by country. Countries were also ranked the by recipients' total number of barriers. Intra-class correlations were calculated at country and center level. The five most frequently mentioned barriers were sleepiness (27.1%), being away from home (25.2%), forgetfulness (24.5%), interruptions to daily routine (23.6%) and being busy (22.8%), fairly consistently across countries. The participants reported on average three barriers, ranging from zero up to 22 barriers. The majority of the variability among reported barriers frequency was situated at the recipient level (94.8%). We found limited international variability in primarily person-level barriers in our study. Understanding of barriers in variable contexts guides intervention development to support adherence to the immunosuppressive regimen in real-world settings.


Assuntos
Transplante de Coração , Imunossupressores , Adesão à Medicação , Humanos , Imunossupressores/uso terapêutico , Adesão à Medicação/estatística & dados numéricos , Masculino , Feminino , Estudos Transversais , Pessoa de Meia-Idade , Adulto , Inquéritos e Questionários , Idoso , Transplantados , Autorrelato , Rejeição de Enxerto/prevenção & controle , Análise de Dados Secundários
15.
Transpl Int ; 37: 13215, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39267617

RESUMO

Solid organ transplantation has progressed rapidly over the decades from the first experimental procedures to its role in the modern era as an established treatment for end-stage organ disease. Solid organ transplantation including liver, kidney, pancreas, heart, and lung transplantation, is the definitive option for many patients, but despite the advances that have been made, there are still significant challenges in meeting the demand for viable donor grafts. Furthermore, post-operatively, the recipient faces several hurdles, including poor early outcomes like primary graft dysfunction and acute and chronic forms of graft rejection. In an effort to address these issues, innovations in organ engineering and treatment have been developed. This review covers efforts made to expand the donor pool including bioengineering techniques and the use of ex vivo graft perfusion. It also covers modifications and treatments that have been trialed, in addition to research efforts in both abdominal organs and thoracic organs. Overall, this article discusses recent innovations in machine perfusion and organ bioengineering with the aim of improving and increasing the quality of donor organs.


Assuntos
Bioengenharia , Preservação de Órgãos , Transplante de Órgãos , Perfusão , Humanos , Perfusão/métodos , Bioengenharia/métodos , Transplante de Órgãos/métodos , Preservação de Órgãos/métodos , Rejeição de Enxerto/prevenção & controle , Doadores de Tecidos/provisão & distribuição
16.
Transpl Int ; 37: 13232, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39267618

RESUMO

The diagnosis of liver antibody-mediated rejection (AMR) is challenging and likely under-recognized. The association of AMR with donor-specific antibodies (DSA), and its clinical course in relation to pathologic findings and treatment are ill defined. We identified cases of liver AMR by following the criteria outlined by the 2016 Banff Working Group. Patient demographics, native liver disease, histopathologic findings, treatment type, clinical outcome, and transaminase levels during AMR diagnosis, treatment, and resolution were determined. Patients (n = 8) with AMR average age was 55.2 years (range: 19-68). Seven of eight cases met the Banff criteria for AMR. Personalized treatment regimens consisted of optimization of immunosuppression, intravenous pulse steroids, plasmapheresis, IVIG, rituximab, and bortezomib. Five patients experienced complete resolution of AMR, return of transaminases to baseline, and decreased DSA at long-term follow-up. One patient developed chronic AMR and two patients required re-transplantation. Follow-up after AMR diagnosis ranged from one to 11 years. Because AMR can present at any time, crossmatch, early biopsy, and routine monitoring of DSA levels should be implemented following transaminase elevation to recognize AMR. Furthermore, treatment should be immediately implemented to reverse AMR and prevent graft failure, chronic damage, re-transplantation, and possibly mortality.


Assuntos
Rejeição de Enxerto , Transplante de Fígado , Humanos , Rejeição de Enxerto/imunologia , Pessoa de Meia-Idade , Adulto , Masculino , Feminino , Idoso , Seguimentos , Adulto Jovem , Isoanticorpos/imunologia , Imunossupressores/uso terapêutico , Fígado/patologia , Rituximab/uso terapêutico , Plasmaferese , Bortezomib/uso terapêutico , Estudos Retrospectivos , Resultado do Tratamento
17.
Front Immunol ; 15: 1407118, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39267737

RESUMO

Background: Islet transplantation is a promising treatment for type 1 diabetes that aims to restore insulin production and improve glucose control, but long-term graft survival remains a challenge due to immune rejection. Methods: ScRNA-seq data from syngeneic and allogeneic islet transplantation grafts were obtained from GSE198865. Seurat was used for filtering and clustering, and UMAP was used for dimension reduction. Differentially expressed genes were analyzed between syngeneic and allogeneic islet transplantation grafts. Gene set variation analysis (GSVA) was performed on the HALLMARK gene sets from MSigDB. Monocle 2 was used to reconstruct differentiation trajectories, and cytokine signature enrichment analysis was used to compare cytokine responses between syngeneic and allogeneic grafts. Results: Three distinct macrophage clusters (Mø-C1, Mø-C2, and Mø-C3) were identified, revealing complex interactions and regulatory mechanisms within macrophage populations. The significant activation of macrophages in allogeneic transplants was marked by the upregulation of allograft rejection-related genes and pathways involved in inflammatory and interferon responses. GSVA revealed eight pathways significantly upregulated in the Mø-C2 cluster. Trajectory analysis revealed that Mø-C3 serves as a common progenitor, branching into Mø-C1 and Mø-C2. Cytokine signature enrichment analysis revealed significant differences in cytokine responses, highlighting the distinct immunological environments created by syngeneic and allogeneic grafts. Conclusion: This study significantly advances the understanding of macrophage roles within the context of islet transplantation by revealing the interactions between immune pathways and cellular fate processes. The findings highlight potential therapeutic targets for enhancing graft survival and function, emphasizing the importance of understanding the immunological aspects of transplant acceptance and longevity.


Assuntos
Rejeição de Enxerto , Transplante das Ilhotas Pancreáticas , Macrófagos , Análise de Célula Única , Transplante das Ilhotas Pancreáticas/imunologia , Transplante das Ilhotas Pancreáticas/métodos , Macrófagos/imunologia , Macrófagos/metabolismo , Animais , Rejeição de Enxerto/imunologia , Camundongos , Citocinas/metabolismo , Sobrevivência de Enxerto/imunologia , Diabetes Mellitus Tipo 1/imunologia , Diabetes Mellitus Tipo 1/cirurgia , Transplante Homólogo , Perfilação da Expressão Gênica , Ativação de Macrófagos/genética , Transcriptoma
18.
Front Immunol ; 15: 1433469, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39286256

RESUMO

Lung transplantation offers a lifesaving option for patients with end-stage lung disease, but it is marred by a high risk of post-transplant infections, particularly involving multidrug-resistant bacteria, Cytomegalovirus, and fungal pathogens. This elevated infection rate, the highest among solid organ transplants, poses a significant challenge for clinicians, particularly within the first year post-transplantation, where infections are the leading cause of mortality. The direct exposure of lung allografts to the external environment exacerbates this vulnerability leading to constant immune stimulation and consequently to an elevated risk of triggering alloimmune responses to the lung allograft. The necessity of prolonged immunosuppression to prevent allograft rejection further complicates patient management by increasing susceptibility to infections and neoplasms, and complicating the differentiation between rejection and infection, which require diametrically opposed management strategies. This review explores the intricate balance between preventing allograft rejection and managing the heightened infection risk in lung transplant recipients.


Assuntos
Rejeição de Enxerto , Transplante de Pulmão , Humanos , Transplante de Pulmão/efeitos adversos , Rejeição de Enxerto/imunologia , Animais , Terapia de Imunossupressão
19.
J Med Case Rep ; 18(1): 408, 2024 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-39232822

RESUMO

BACKGROUND: Tacrolimus is a potent calcineurin inhibitor (CNI) that is principally used as a first-line immunosuppressant for the prophylaxis of allograft rejection in liver transplantation (LT) patients. In clinical practice, prescribing the optimal tacrolimus dosage is complicated by its narrow therapeutic index and high pharmacokinetic variability. Thus, performing therapeutic drug monitoring (TDM) of only tacrolimus may not provide optimal drug levels. However, other influential clinical factors affecting tacrolimus levels, such as hemoglobin (Hb), hematocrit, and total bilirubin (TBIL), should be considered while adjusting tacrolimus levels. This case report aims to introduce clinicians and their teams to taking the pharmacokinetic prediction equation into consideration for a better understanding of tacrolimus dosage adjustment during the early postoperative LT. CASE PRESENTATION: In this case report, an 18-year-old male patient of Thai ethnicity was admitted for orthotropic liver transplantation, and tacrolimus was prescribed as a cornerstone immunosuppressive agent. In the immediate postoperative period, which is the most challenging period in liver transplantation, the population pharmacokinetics predictive equation was clinically used to assist in dosage adjustment of tacrolimus by considering the significant clinical factors in this case. Hemoglobin and total bilirubin levels were deemed significant clinical factors affecting the oral clearance (CL/F) of tacrolimus. First, a decrease in the Hb concentration increases the free drug concentration and therefore increases the CL/F of tacrolimus. Second, an elevated TBIL decreases the biliary excretion of tacrolimus, resulting in a decrease in the CL/F of tacrolimus. Thus, dose optimization of tacrolimus would be accurate when taking the pharmacokinetic prediction equation into consideration. Moreover, the results may contribute to a better understanding of tacrolimus pharmacokinetic variability in each transplant patient during the immediate postoperative course. CONCLUSIONS: Hemoglobin and total bilirubin were significant clinical factors influencing the oral clearance of tacrolimus early after liver transplantation. A decrease in the hemoglobin concentration would increase the free drug concentration and therefore increase the oral clearance of tacrolimus. An elevated total bilirubin decreases the biliary excretion of tacrolimus, resulting in a decrease in the oral clearance of tacrolimus.


Assuntos
Bilirrubina , Monitoramento de Medicamentos , Hemoglobinas , Imunossupressores , Transplante de Fígado , Tacrolimo , Humanos , Tacrolimo/farmacocinética , Tacrolimo/administração & dosagem , Masculino , Bilirrubina/sangue , Imunossupressores/farmacocinética , Imunossupressores/administração & dosagem , Adolescente , Hemoglobinas/análise , Período Pós-Operatório , Rejeição de Enxerto/prevenção & controle
20.
Sci Rep ; 14(1): 20357, 2024 09 02.
Artigo em Inglês | MEDLINE | ID: mdl-39223175

RESUMO

In kidney transplant recipients, urine CXCL9 and CXCL10 (uCXCL9/10) chemokines have reached a sufficiently high level of evidence to be recommended by the European Society of Organ Transplantation for the monitoring of immune quiescence. To assess the risk of acute rejection (AR), the advantage of uCXCL9/10 is their cost-effectiveness and their high diagnostic performance. Here, we evaluated the feasibility of a next-generation immunoassay for quantifying uCXCL9/10 levels. It demonstrated high efficiency with minimal workflow and a 90-min time to result. Preanalytical studies indicated stability of uCXCL9/10 levels and analytical studies confirmed excellent linearity and precision. In a cohort of 1048 samples collected at biopsy, the results correlated significantly with ELISA quantification and were integrated into a previously validated 8-parameter urine chemokine model. The next generation immunoassay achieved an accuracy of 0.84 for AR diagnosis. This study validates this technology as a robust, locally available and unexpensive platform and marks a significant step towards the widespread implementation of uCXCL9/10, for immune quiescence monitoring. Therefore, we developed an open-access web application using uCXCL9/10 to calculate AR risk and improve clinical decision-making to perform biopsy, ushering in a new era in kidney transplantation, where personalized, data-driven care becomes the norm.


Assuntos
Quimiocina CXCL10 , Quimiocina CXCL9 , Rejeição de Enxerto , Transplante de Rim , Transplante de Rim/efeitos adversos , Quimiocina CXCL10/urina , Humanos , Quimiocina CXCL9/urina , Rejeição de Enxerto/urina , Rejeição de Enxerto/diagnóstico , Masculino , Feminino , Pessoa de Meia-Idade , Biomarcadores/urina , Adulto , Idoso , Imunoensaio/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA